Neuroprotection of Retinal Ganglion Cells by VEGF-B
About the Research Project
Program
Award Type
Standard
Award Amount
$88,920
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
G2007005
Acknowledgement
Goals
We hypothesize that VEGF-B may have a neuroprotective effect on the retinal ganglion cells. To test this hypothesis, we will use multiple approaches and methods, including both normal and VEGF-B transgenic mice, both protein and gene transfer, both gain and loss of function analysis, to investigate the neuroprotective effect of VEGF-B on retinal ganglion cells in vivo.
Summary
Glaucoma is the most prevalent form of adult optic neuropathy characterized by the degeneration and death of the retinal ganglion cells (RGCs). Molecules with neuroprotective effect on the endangered RGCs are therefore much desired to preserve and rescue the RGCs and thus the vision of glaucoma patients. This research proposal is therefore designed to test in vivo the neuroprotective effect of one such candidate molecule, the vascular endothelium growth factor B (VEGF-B), and to further characterize the molecular and cellular mechanisms underlying. VEGF-B has been shown to be a critical neuroprotective factor in the brain. Our current work has shown that VEGF-B may play important roles in the retina. The outcome of this study may lead to possibilities of novel therapy for glaucoma patients and more insight into the course of glaucoma.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego